Friday, May 1, 2026

North Korea’s Kim Jong Un Declares South Korea ‘Hostile’: What This Means for Peace in 2026

North Korea's Kim Jong Un labels South Korea as hostile, prompting the Blue House to advocate for dialogue and peaceful coexistence.

Hanwha’s Bold Move: South Korean Defense Firms Join U.S. Navy’s Next-Gen Support Ship Project

Hanwha's shipyard and Hanwha Defense USA join the U.S. Navy's next-gen support ship design project, marking a significant collaboration.

Stadiums Empty? Shocking Truth About Paris 2024 Ticket Sales

The resale site for the Paris Olympics has seen an increase in ticket inventory, growing from 180,000 tickets a month ago to 271,637.

Tag: drug

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

KVMA and KIDS to Enhance the Safety Management of Narcotic Drugs in Veterinary Medicine

The KVMA and KIDS signed an MOU to enhance narcotic drug safety in veterinary medicine, promoting education and data utilization.

ADHD Medication Misconceptions: Why Korean Teens Are Misusing Study Drugs

ADHD medications are misused by teens as smart drugs. The Ministry of Food and Drug Safety expands education and AI monitoring to combat this.

Penetrium Bioscience Announces Finalization of New Clinical Strategy for Targeted Cancer Therapies

Penetrium Bioscience reveals new clinical strategy to combat drug resistance in cancer therapies at AACR 2026, launching Phase 2 trials.

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

Nesuparib: The Game-Changing Cancer Treatment for Small Cell Lung Cancer Revealed at AACR 2026

Onconic Therapeutics reveals Nesuparib's promising preclinical results for small cell lung cancer, outperforming existing treatments significantly.

YH35995: A Game-Changer for Gaucher Disease? FDA Grants Orphan Drug Designation

Yuhan Corp's YH35995 for Gaucher disease receives orphan drug designation, enhancing its development for rare diseases with unmet needs.

Daewoong Pharmaceutical Expands Indication for Fexuclue: What This Means for 2026

Daewoong Pharmaceutical submits Phase 3 trial plan for Fexuclue to treat gastric ulcers, aiming to enhance treatment options and patient quality of life.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

GI-101A: Breakthrough Immuno-Oncology Drug Set for ASCO 2026 Presentation

GI Innovation's GI-101A will be presented at ASCO 2026, highlighting its clinical potential and significance in oncology.

Over Half of Top Propofol-Using Clinics in Asia Found Violating Drug Control Law

Authorities found widespread narcotics violations in medical institutions using propofol, with over half inspected breaching regulations.

Pangen Expands Cell-Based Bioassay Services for Customized Drug Development

Pangen is expanding its cell-based activity analysis services after a new contract, enhancing drug evaluation capabilities for various medications.

Unlocking Cancer Treatment: How TXN12923 Targets ULK1 for Enhanced Drug Sensitivity

Txinno Bioscience to present TXN12923, a novel ULK1 targeted protein degrader, at AACR, aiming to enhance cancer treatment efficacy.

Daewoong’s Hub System Aims to End Drug Shortages With Predictive Data

Daewoong Pharmaceutical is enhancing drug distribution with a data-driven hub system for better inventory management and transparency.

Huons BioPharma’s Botulinum Toxin HUTOX Set to Transform the Chinese Market

Huons BioPharma partners with iMaker Technology to supply botulinum toxin, aiming for a strong market presence in China.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.